Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Articles

States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.

How State Substitution Laws Shape Insulin Biosimilar Adoption

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

Cameron Santoro is an associate editor for The Center for Biosimilars

Videos

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.

Experts Pressure Congress to Remove Roadblocks for Biosimilars

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Global Perspective on the Effect of Biosimilars

Comparison of Biologics to Biosimilars Versus Generics

The BPCIA and the Naming of Biosimilars

The Approval Process for Biosimilars

Considerations for Approving Generics Versus Biosimilars 

Interchangeability and Postmarketing Pharmacovigilance of Biosimilars

Experience Prescribing Biosimilars Versus Biologics

The Impact of Access to Biosimilars

US and EU Biosimilar Pricing and Stakeholder Education

Formulary Approval and Challenges for Payers

Prescribing Biosimilars and Educating Patients and Physicians 

The Influence of Biosimilars in Cancer Care

Biosimilars in the Pipeline and Disease Management

Outlook on the Future of Biosimilars 